Changes to the website
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

This is a list of chages to the website.

You can Subscribe to our RSS FEED: Subscribe to our RSS feed, which delivers brain tumor news and additions to the website via RSS.
(Click HERE for details on RSS.)

Displaying items 26 to 50 of about 4561

Previous 25           Next 25
Website Changes
12/02/2017 Novocure (NVCR) Announces Reimbursement Approval for Optune in Japan for Treatment of Newly Diagnosed GBM
12/02/2017 SNO 2017: Toca 511/FC Lead to Durable Responses in IDH1 Wildtype and Mutant Recurrent High-Grade Glioma
12/02/2017 Novel Agents for GBM and Glioma From SNO 2017
12/02/2017 Key Trials on Gliomas at SNO 2017
12/02/2017 SNO 2017: No Unexpected Safety Issues Arise With Tumor Treating Fields in Glioblastoma Patients With Shunts, Pacemakers, or Defibrillators
12/02/2017 Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma
12/02/2017 Researchers identify vulnerability for glioblastoma subtypes
12/02/2017 Novel Agents for GBM: A Review of Trials at SNO 2017
12/01/2017 FDA Aims to Expand Early-Approval Program for Promising Drugs
11/24/2017 Effectiveness of ONC201 in H3 K27M Glioma to be Presented at SNO
11/24/2017 Ziopharm says its brain cancer drug helped trial patients live more than a year
11/24/2017 Inovio Starts Trial Testing Triple-combo Immunotherapy in Newly-diagnosed Glioblastoma
11/22/2017 Medicenna Presents Updates on Phase 2b Clinical Trial of MDNA55 at the Annual Meeting of the Society of Neuro-Oncology
11/21/2017 High compliance with Optune linked to greatest survival benefit for glioblastoma
11/21/2017 Lomustine and Bevacizumab in Progressive Glioblastoma.
11/21/2017 Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit.
11/21/2017 DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting
11/17/2017 Toca 5 Trial is now open!
11/17/2017 GBM Heroes Honored By CURE
11/17/2017 Patients Who Used Optune® More Than 90 Percent of the Time Had the Greatest Chance of Survival in Novocure’s EF-14 Trial: A Median Survival of 24.9 Months from Randomization and a Five-Year Survival of 29.3 Percent
11/16/2017 National Cancer Institute designates UCLA brain cancer program a site of research excellence
11/15/2017 Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
11/15/2017 Medicenna Presents Clinical Data From Previous Phase 1 and 2 Clinical Trials of MDNA55
11/10/2017 Human fibulin-3 protein variant expresses anti-cancer effects in the malignant glioma extracellular compartment in intracranial xenograft models
11/07/2017 Liquid Biopsy Spots Aggressive Pediatric Brainstem Cancer Earlier



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites